Results 11 to 20 of about 5,013 (195)

A Case of Possible Infusion-Related Reactions Caused by Palonosetron

Case Reports in Oncology
Introduction: An infusion-related reaction (IRR) is an adverse event that typically occurs when cytotoxic drugs or monoclonal antibodies are administered.
Toru Kadono, Hiroyuki Kodama, Hiroki Yukami, Toshifumi Yamaguchi, Hiroki Nishikawa   +4 more
doaj   +2 more sources

Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Cisplatin (CDDP)-induced nephrotoxicity is the most important complication of CDDP treatment. 5-Hydroxytryptamine type 3 receptor antagonists (5-HT3RAs) are widely used to prevent chemotherapy-induced nausea and vomiting (CINV).
Miho Takemura, Kenji Ikemura, Masayoshi Kondo, Fumihiro Yamane, Mikiko Ueda, Masahiro Okuda   +5 more
doaj   +2 more sources

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study

Frontiers in Pharmacology, 2022
Objective: To test the hypothesis that the single use of fosaprepitant is not inferior to the use of palonosetron as antiemetic prophylaxis in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy.Method: Eighty-eight nonsmoking ...
Estêvão Luiz Carvalho Braga, Nubia Verçosa, Ismar Lima Cavalcanti   +2 more
doaj   +2 more sources

Comparative evaluation of ondansetron, palonosetron, and dexamethasone for antiemetic prophylaxis in cesarean section under spinal anaesthesia

Asian Journal of Medical Sciences
Background: Spinal anesthesia is the most common regional anesthesia used to provide surgical anesthesia for cesarean section. Nausea and vomiting are common symptoms experienced by patients undergoing cesarean section. Aims and Objectives: The aim of
Vankudoth Bhaskar , Jitendra Agrawal , Ankita Gupta , Ashish Mohan M   +3 more
doaj   +2 more sources

5-HT₃ receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta-analysis. [PDF]

Int J Gynaecol Obstet
Abstract Background Gynecological surgery is generally associated with a high risk of postoperative nausea and vomiting (PONV), for which a combination of antiemetic therapies is advised, but adherence to these protocols is often low. Given the current reality, a preferred 5‐HT3 receptor antagonist for preventing PONV as a result of gynecological ...
Xu H, Rong L, Yang S, Xing J, Dong H, Liu H, Chen X, Liu L.   +7 more
europepmc   +2 more sources

Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study [PDF]

Journal of Geriatric Oncology, 2023
Luigi Celio, Rupert Bartsch, Matti Aapro
openalex   +2 more sources

Comparison of the efficacy of acupressure on P6 point, dexamethasone and ondansetron versus palonosetron monotherapy for preventing postoperative nausea and vomiting in laparoscopic surgery

Anaesthesia, Pain & Intensive Care, 2023
Background: Postoperative nausea and vomiting (PONV) is a common occurrence, affecting approximately 70-80% of patients who have undergone surgery, particularly those with multiple risk factors.
Chiong Woei Zhong, Ariffin Marzuki Mokhtar, Nik Abdullah Nik Mohammad, Mahamarowi Omar, Nurul Aifaa Mohd Azmi, Mohd Zulfakar Mazlan   +5 more
openalex   +3 more sources

NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. [PDF]

Cancer Med
This study was designed to evaluate the use of NEPA (netupitant/palonosetron) plus dexamethasone with or without olanzapine for the prevention of CINV in the second cycle of chemotherapy for patients receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) who developed breakthrough CINV in their first cycle despite guideline‐directed ...
Navari RM, Bonizzoni E.
europepmc   +2 more sources

Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. [PDF]

Oncologist
Background Despite guidelines for managing chemotherapy-induced nausea and vomiting (CINV), there remains a need to clarify the optimal use of neurokinin-1 (NK1) receptor antagonists.
Luo WT, Chang CL, Huang TW, Gautama MSN.
europepmc   +2 more sources

Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis [PDF]

Journal of Personalized Medicine, 2022
This updated systematic review and meta-analysis with trial sequential analysis aimed to compare the efficacy of the perioperative administration of palonosetron with that of ramosetron in preventing postoperative nausea and vomiting (PONV).
Hyo Jin Kim, Eun Jin Ahn, Geun Joo Choi, Hyun Kang   +3 more
openalex   +2 more sources